General Information of Drug (ID: DMST5HF)

Drug Name
Nofazinlimab Drug Info
Synonyms EQ176; CS1003
Indication
Disease Entry ICD 11 Status REF
Liver cancer 2C12 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMST5HF

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Programmed cell death protein 1 (PD-1) TTNBFWK PDCD1_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Programmed cell death protein 1 (PD-1) DTT PDCD1 5.635 4.661 4.706 5.15
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Liver cancer
ICD Disease Classification 2C12
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Programmed cell death protein 1 (PD-1) DTT PDCD1 7.26E-01 -0.01 -0.03
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04194775) A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of Nofazinlimab (CS1003) in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Advanced Hepatocellular Carcinoma (HCC). U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of EQRx